By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Milo Biotechnology 

Cleveland  Ohio    U.S.A.
Phone: n/a Fax: n/a



Company News
Milo Biotechnology Announces FDA Orphan Drug Designation For Treatment Of Inclusion Body Myositis 10/4/2016 12:49:30 PM
JumpStart And Rev1 Ventures Announce Investment In Milo Biotechnology 9/20/2016 9:21:45 AM
Milo Biotechnology Release: Follistatin Gene Therapy Increases Function In Inclusion Body Myositis Patients 5/10/2016 1:10:39 PM
Milo Biotechnology Release: First Duchenne Muscular Dystrophy Patient Treated In Follistatin Gene Therapy Trial 4/13/2015 7:37:30 AM
Milo Biotechnology Announces Patent Issuance 12/3/2014 11:52:37 AM
The Duchenne Alliance Commits $500,000 To Jerry Mendell M.D. And Milo Biotechnology To Fund First Duchenne Follistatin Gene Therapy Trial 11/17/2014 3:28:15 PM
Milo Biotechnology's Follistatin Gene Therapy Increases Function In Becker Muscular Dystrophy Patients 10/20/2014 9:18:11 AM
Milo Biotechnology Announces DSG, Inc. Orphan Drug Designation for AAV1-FS344 for Treatment of Duchenne and Becker Muscular Dystrophy 12/12/2012 9:46:02 AM